Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

3 Lucrative Pharma Stocks to Diversify Your Investments

The pharma industry’s resilience and long-term prospects are driven by rising healthcare demand, an enhanced focus on precision medicines, and technological advancements. Hence, let’s take a look at pharma stocks Perrigo Company (PRGO), Amneal Pharmaceuticals (AMRX), and Supernus Pharmaceuticals (SUPN), which could diversify your investments. Read on….

StockNews.com

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst

Sarepta will likely miss first-quarter expectations, an analyst said Monday, noting Sarepta stock has taken a beating since its last report.

Investors Business Daily

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

IBD Stock Of The Day Novo Nordisk: Why A Pullback Is Bullish For The Weight-Loss Kingpin

The company leads the weight-loss drugs market with its blockbuster, Wegovy. But next-generation drugs are coming.

Investors Business Daily

Aurora Cannabis (ACB) vs. Merck (MRK): Which Pharma Stock Holds Greater Potential for Investors?

The pharmaceutical industry is poised for robust growth owing to technological advancements and growing healthcare needs. Given this backdrop, let’s analyze Aurora Cannabis (ACB) and Merck & Co. (MRK) to determine which of the two stocks holds greater potential for investors. Read on….

StockNews.com

Cheaper private Covid jabs may end up as costly as pricier ones, say experts

Exclusive: Multi-dose vials could push up charge per patient, with experts warning cost could widen inequalities

The Guardian - UK

NPPA revises ceiling prices of over 800 scheduled drug formulations from April 1

Cost of antibiotics and painkillers have registered a marginal hike in cost starting with the drug price regulator National Pharmaceutical Pricing Authority’s latest notification

The Hindu

Read news from The Economist, FT, and more,
with one subscription

Uber Leads Five Stocks Near Buy Points

Uber, Axon and one more stock with the highest-possible rating from IBD lead this weekend's watch list.

Investors Business Daily

Drug Company's Libel Lawsuit Against Scientists Dismissed

From yesterday's decision by Judge Gregory Woods (S.D.N.Y.) in Cassava Sciences, Inc. v. Bredt: Cassava Sciences, Inc. ("Cassava") is a biotechnology company that is conducting clinical trials for an Alzheimer's drug called simufilam. Following the second phase of the simufilam clinical trials, multiple short sellers, most of them scientists, published…

Reason

Nearly 1,000 pharmacies in England closed since 2017, with poorer areas more affected

Exclusive: Millions more GP appointments potentially created as a result of closures

The Guardian - UK

Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why

Crispr stock is down for the fifth straight week as the top Cathie Wood's holding struggles amid dim expectations for its gene-editing drug.

Investors Business Daily

New List Out On Medicare Part B Drugs Eligible for Rebates

Some Medicare beneficiaries may pay lower coinsurance rates from April 1 to June 30 for the drugs, HHS says.

Kiplinger

19th Century law versus bodily autonomy

Abortion opponents are citing the Comstock Act to stop "abortion pill trafficking." Experts say that's nonsense

Salon

How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback

Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Jumps Early Entry As Viking Charges Obesity Space

Eli Lilly stock is Wednesday's IBD Stock Of The Day. Shares are forming a flat base as competition mounts for its weight-loss drug, Zepbound.

Evening Standard

'Everywhere I look private companies are more valuable': Biotech firm C4X becomes latest to quit London stock market

Biotech firm C4X today became the latest business to abandon the London stock market after is said its future growth would be better secured through private investment.

France 24

US Supreme Court hears arguments in abortion pill case

U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Merck Stock Pops After Snagging Its Latest Approval; The First In A Possible $10 Billion 'Renaissance'

Merck stock popped Wednesday, pacing the Dow Jones industrials, after winning FDA approval for its new pulmonary arterial hypertension drug.

Axios

Abortion pill ruling could be "catastrophic" for new drug development

"It would be a catastrophic event."

Top News

Supreme Court To Decide High-Stakes Abortion Pill Case

The Supreme Court's upcoming decision on mifepristone's approval process could have significant implications for reproductive rights and healthcare access ...

The Texas Tribune

U.S. Supreme Court takes up Texas case challenging abortion pill access

A majority of Supreme Court justices seemed open to keeping mifepristone, a common abortion-inducing drug, on the market despite a Texas ruling revoking its FDA approval.

Axios

SCOTUS abortion pill hearing puts FDA discretion on trial

A ruling against expanded mifepristone access could set a precedent for courts to substitute their own conclusions for agency decisions.

The Guardian - US

How the abortion pill case at the supreme court could undo the FDA

The mifepristone case is viewed with trepidation by the medical industry and could have enormous consequences for drug regulation

The Guardian - UK

US-style executive pay packets in UK would ‘risk higher inequality’

Leading social scientists issue warning after call by business leaders and London Stock Exchange

1 … 13 14 15 16

People

Clarence Thomas

1,389 stories

Ketanji Brown Jackson

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.